NCT07616986Recruiting
LITT for Ultra-early GBM Recurrence
Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 24 Nov 2025
- Start date
- 6 Feb 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Glioblastoma
- NCT number
- NCT07616986
What you commit to
- Study type: Interventional
- Planned participants: 12
- From 6 Feb 2026 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
- ≥18 years of age
- CRET
- Karnofsky Performance Status (KPS) ≥70
- No contra-indication for radio-chemotherapy
- Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
- Able to provide informed consent
- No contra-indication for LITT
- No pregnancy or active breast-feeding
- No known coagulopathy independent of medication
- No dissemination or multifocal disease
- Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dep. of Neurosurgery, Bern University Hospital Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.